As a result, this pathway is activated in cancer cells through various mechanisms involving genomic alterations in the pathway components (e.g., PIK3CA, PIK3R1, PTEN, AKT, TSC1, TSC2, LKB1), some of which are therapeutic targets. This evidence concerns the gene AKT1 and cancer.